List view / Grid view
18 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...
17 November 2014 | By Probiodrug
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences...
17 November 2014 | By Moberg Pharma
Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012...
17 November 2014 | By Moberg Pharma
"We made excellent progress in the third quarter, growing at 35% with improved profitability and reporting strong phase II data for MOB-015 in nail fungus..."
17 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418)...
17 November 2014 | By The International Longevity Centre
Councils must ensure that spending cuts and short term targets do not undermine long-term investment in the prevention of ill health in old age...
17 November 2014 | By Medidata
Joint initiative evaluates impact of mHealth and cloud-based technologies on patient engagement, data quality and operational efficiencies in clinical trials...
17 November 2014 | By Roche
Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent compared to chemotherapy alone in a Phase III study...
14 November 2014 | By MedImmune and Advaxis
Dose confirmation safety study of ADXS-HPV and MEDI4736 combination therapy to initiate in early 2015...
14 November 2014 | By GlaxoSmithKline
GSK launched the first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into non-communicable diseases (NCDs) in Africa...
14 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio...
14 November 2014 | By Genticel
Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix...
14 November 2014 | By Moberg Pharma
Moberg Pharma’s partner in Southeast Asia and China, Menarini APAC, has initiated the launch in Malaysia of Moberg Pharma’s prescription-free treatment for nail fungus...
14 November 2014 | By Roche
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection...
13 November 2014 | By SELECTBIO
SELECTBIO is delighted to announce that Screening Europe is back...
